Page 110 - Read Online

Zhang et al. Hepatoma Res 2020;6:40 I http://dx.doi.org/10.20517/2394-5079.2020.20 Page 9 of 12

protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma. Cancer Immunol
Immunother 2019;68:353-63.
27. Cheng HY, Kang PJ, Chuang YH, Wang YH, Jan MC, et al. Circulating programmed death-1 as a marker for sustained high hepatitis B
viral load and risk of hepatocellular carcinoma. PLoS One 2014;9:e95870.
28. Li N, Zhou Z, Li F, Sang J, Han Q, et al. Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from
other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection. Oncotarget 2017;8:46020-
33.
29. Liang L, Ge K, Zhang F, Ge Y. The suppressive effect of co-inhibiting PD-1 and CTLA-4 expression on H22 hepatomas in mice. Cell
Mol Biol Lett 2018;23:58.
30. Song B, Zhen S, Meng F. T cell inflammation profile after surgical resection may predict tumor recurrence in HBV-related hepatocellular
carcinoma. Int Immunopharmacol 2016;41:35-41.
31. Liu F, Zeng G, Zhou S, He X, Sun N, et al. Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-
related hepatocellular carcinoma. Bull Cancer 2018;105:493-501.
32. He G, Zhang H, Zhou J, Wang B, Chen Y, et al. Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1
signalling pathway in hepatocellular carcinoma. J Exp Clin Cancer Res 2015;34:141.
33. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, et al. Nivolumab in patients with advanced hepatocellular carcinoma
(CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-502.
34. Finkelmeier F, Czauderna C, Perkhofer L, Ettrich TJ, Trojan J, et al. Feasibility and safety of nivolumab in advanced hepatocellular
carcinoma: real-life experience from three German centers. J Cancer Res Clin Oncol 2019;145:253-9.
35. Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously
treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018;19:940-52.
36. Marquardt JU, Saborowski A, Czauderna C, Vogel A. The changing landscape of systemic treatment of advanced hepatocellular
carcinoma: new targeted agents and immunotherapies. Target Oncol 2019;14:115-23.
37. Qin SK, Ren ZG, Meng ZQ, Chen ZD, Chai XL, et al. A randomized multicentered phase II study to evaluate SHR-1210 (PD-1
antibody) in subjects with advanced hepatocellular carcinoma (HCC) who failed or intolerable to prior systemic treatment. Ann Oncol
2018;29:viii719-20.
38. Llopiz D, Ruiz M, Villanueva L, Iglesias T, Silva L, et al. Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the
histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model. Cancer Immunol Immunother 2019;68:379-93.
39. Li H, Li X, Liu S, Guo L, Zhang B, et al. Programmed cell death-1 (PD-1) checkpoint blockade in combination with a mammalian target
of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1. Hepatology 2017;66:1920-33.
40. Chen ML, Yan BS, Lu WC, Chen MH, Yu SL, et al. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in
tumor microenvironment to augment antitumor immunity. Int J Cancer 2014;134:319-31.
41. Kimura T, Kato Y, Ozawa Y, Kodama K, Ito J, et al. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the
Hepa1-6 hepatocellular carcinoma model. Cancer Sci 2018;109:3993-4002.
42. Butty V, Roy M, Sabeti P, Besse W, Benoist C, et al. Signatures of strong population differentiation shape extended haplotypes across the
human CD28, CTLA4, and ICOS costimulatory genes. Proc Natl Acad Sci USA 2007;104:570-5.
43. Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA. CD28 costimulation: from mechanism to therapy. Immunity 2016;44:973-88.
44. Valk E, Rudd CE, Schneider H. CTLA-4 trafficking and surface expression. Trends Immunol 2008;29:272-9.
45. Yang J, Liu J, Chen Y, Tang W, Liu C, et al. Association of CTLA-4 tagging polymorphisms and haplotypes with hepatocellular
carcinoma risk: a case-control study. Medicine (Baltimore) 2019;98:e16266.
46. Wang C, Liu W, Zhao L, Dong Z. Association of cytotoxic T-lymphocyte antigen-4 + 49A/G gene polymorphism with hepatocellular
carcinoma risk in Chinese. J Cancer Res Ther 2018;14:S1117-20.
47. Hu L, Liu J, Chen X, Zhang Y, Liu L, et al. CTLA-4 gene polymorphism +49 A/G contributes to genetic susceptibility to two infection-
related cancers-hepatocellular carcinoma and cervical cancer. Hum Immunol 2010;71:888-91.
48. Gu X, Qi P, Zhou F, Ji Q, Wang H, et al. +49G > A polymorphism in the cytotoxic T-lymphocyte antigen-4 gene increases susceptibility
to hepatitis B-related hepatocellular carcinoma in a male Chinese population. Hum Immunol 2010;71:83-7.
49. Sangro B, Gomez-Martin C, de la Mata M, Inarrairaegui M, Garralda E, et al. A clinical trial of CTLA-4 blockade with tremelimumab in
patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013;59:81-8.
50. Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, et al. Tremelimumab in combination with ablation in patients
with advanced hepatocellular carcinoma. J Hepatol 2017;66:545-51.
51. Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, et al. Antitumor activity in melanoma and anti-self responses in a
phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 2005;23:8968-77.
52. Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, et al. Safety and antitumour activity of durvalumab plus tremelimumab
in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol 2016;17:299-308.
53. Xie C, Duffy AG, Mabry-Hrones D, Wood B, Levy E, et al. Tremelimumab in combination with microwave ablation in patients with
refractory biliary tract cancer. Hepatology 2019;69:2048-60.
54. Agdashian D, ElGindi M, Xie C, Sandhu M, Pratt D, et al. The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in
patients with hepatocellular carcinoma. Cancer Immunol Immunother 2019;68:599-608.
55. Mohty M, Gautier J, Malard F, Aljurf M, Bazarbachi A, et al. CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma:
current status and perspectives. Leukemia 2019;33:2767-78.